IL152793A0 - PROCESS FOR THE SYNTHESIS OF (2R, 2-ALPHA-R, 3a)-2-[1-(3,5-BIS(TRIFLUOROMETHYL)PHENYL]-3-(4-FLUOROPHENYL)-1,4-OXAZINE - Google Patents

PROCESS FOR THE SYNTHESIS OF (2R, 2-ALPHA-R, 3a)-2-[1-(3,5-BIS(TRIFLUOROMETHYL)PHENYL]-3-(4-FLUOROPHENYL)-1,4-OXAZINE

Info

Publication number
IL152793A0
IL152793A0 IL15279301A IL15279301A IL152793A0 IL 152793 A0 IL152793 A0 IL 152793A0 IL 15279301 A IL15279301 A IL 15279301A IL 15279301 A IL15279301 A IL 15279301A IL 152793 A0 IL152793 A0 IL 152793A0
Authority
IL
Israel
Prior art keywords
oxazine
fluorophenyl
trifluoromethyl
alpha
bis
Prior art date
Application number
IL15279301A
Other languages
English (en)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of IL152793A0 publication Critical patent/IL152793A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
IL15279301A 2000-06-08 2001-06-04 PROCESS FOR THE SYNTHESIS OF (2R, 2-ALPHA-R, 3a)-2-[1-(3,5-BIS(TRIFLUOROMETHYL)PHENYL]-3-(4-FLUOROPHENYL)-1,4-OXAZINE IL152793A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21020300P 2000-06-08 2000-06-08
PCT/US2001/018042 WO2001094324A1 (en) 2000-06-08 2001-06-04 Process for the synthesis of (2r, 2-alpha-r, 3a)-2-[1-(3,5-bis(trifluoromethyl)phenyl)ethoxy]-3-(4-fluorophenyl)-1,4-oxazine

Publications (1)

Publication Number Publication Date
IL152793A0 true IL152793A0 (en) 2003-06-24

Family

ID=22781976

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15279301A IL152793A0 (en) 2000-06-08 2001-06-04 PROCESS FOR THE SYNTHESIS OF (2R, 2-ALPHA-R, 3a)-2-[1-(3,5-BIS(TRIFLUOROMETHYL)PHENYL]-3-(4-FLUOROPHENYL)-1,4-OXAZINE

Country Status (19)

Country Link
US (1) US6600040B2 (es)
EP (1) EP1292584A1 (es)
JP (1) JP2003535852A (es)
KR (1) KR20030007887A (es)
CN (1) CN1182125C (es)
AR (1) AR030284A1 (es)
AU (1) AU2001268170A1 (es)
BR (1) BR0111472A (es)
CA (1) CA2410404A1 (es)
CZ (1) CZ20024013A3 (es)
EA (1) EA004743B1 (es)
HR (1) HRP20020973A2 (es)
HU (1) HUP0400491A2 (es)
IL (1) IL152793A0 (es)
MX (1) MXPA02012101A (es)
NZ (1) NZ523389A (es)
PL (1) PL359137A1 (es)
SK (1) SK17082002A3 (es)
WO (1) WO2001094324A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001094323A1 (en) * 2000-06-08 2001-12-13 Merck & Co., Inc. Process for the synthesis of (2r, 2-alpha-r)-4-benzyl-2-[1-(3,5-bis(trifluoromethyl)phenyl)ethoxy]-1,4-oxazin-3-one
FR2876101B1 (fr) 2004-10-05 2007-03-02 Sidem Pharma Sa Sa Procede de preparation enantioselective de derives de sulfoxydes
WO2012146692A1 (en) 2011-04-29 2012-11-01 Sandoz Ag Novel intermediates for the preparation of highly pure aprepitant or fosaprepitant
CN103012305B (zh) * 2011-09-23 2016-08-17 江苏豪森药业集团有限公司 一种福沙匹坦中间体的制备方法
CN103030668B (zh) * 2011-10-09 2016-06-15 江苏豪森药业集团有限公司 一种制备福沙匹坦二甲葡胺的方法
CZ304770B6 (cs) 2012-03-13 2014-10-08 Zentiva, K.S. Způsob výroby 3-(((2R,3S)-2-((R)-1-(3,5-bis(trifluormethyl)fenyl)ethoxy)-3-(4-fluorfenyl)morfolino)methyl)-1H-1,2,4-triazol-5(4H)-onu (Aprepitantu) v polymorfní formě II
CN102675240B (zh) * 2012-04-13 2015-01-14 浙江海正药业股份有限公司 4-取代基-2-羟基吗啉-3-酮及其制备方法
CN104327009B (zh) * 2014-09-24 2016-07-20 山东省生物医药科学院 一种阿瑞匹坦关键中间体的精制方法
CN104447607B (zh) * 2014-12-12 2017-02-22 瑞阳制药有限公司 阿瑞匹坦中间体的制备方法
CN104557760A (zh) * 2015-01-28 2015-04-29 武汉励合生物医药科技有限公司 阿瑞吡坦中间体的制备方法
CN106397349A (zh) * 2016-08-31 2017-02-15 安徽省润生医药股份有限公司 一种阿瑞吡坦中间体及其制备方法
CN109516964B (zh) * 2017-09-19 2022-05-31 鲁南制药集团股份有限公司 一种阿瑞匹坦中间体的制备方法
CN109694360A (zh) * 2018-12-28 2019-04-30 凯瑞斯德生化(苏州)有限公司 一种阿瑞匹坦中间体的制备方法
CN110746371B (zh) * 2019-11-20 2022-07-15 山东鲁抗医药股份有限公司 制备阿瑞匹坦的中间体及其制备方法与应用
CN114235340B (zh) * 2020-06-09 2023-11-10 重庆交通大学 河道泡漩结构跟踪方法及通航预警方法
CN111829749A (zh) * 2020-07-27 2020-10-27 中国空气动力研究与发展中心高速空气动力研究所 一种用于风洞超声速流校大行程单点移测装置及布线方法
CN113582982B (zh) * 2021-06-15 2023-06-16 山东罗欣药业集团股份有限公司 一种nk1受体拮抗剂的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719147A (en) * 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
IL111960A (en) * 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
BR9408442A (pt) 1993-12-29 1997-08-05 Merck Sharp & Dohme Composto composição farmacêutica processos para tratamento ou prevenção de distúrbios fisiológicos associados com um excesso de taquiquininas e para a preparação do composto e de uso do composto
ZA985765B (en) 1997-07-02 1999-08-04 Merck & Co Inc Polymorphic form of a tachykinin receptor antagonist.
GB9813025D0 (en) 1998-06-16 1998-08-12 Merck Sharp & Dohme Chemical synthesis
CA2342213A1 (en) * 1998-09-11 2000-03-23 Merck & Co., Inc. Process for the synthesis of n-benzyl-3-(4-fluorophenyl)-1,4-oxazin-2-one
JP2002528546A (ja) 1998-10-30 2002-09-03 メルク エンド カムパニー インコーポレーテッド ２−（ｒ）−（１−（ｒ）−（３，５−ビス（トリフルオロメチル）フェニル）エトキシ−４−（（５−ジメチルアミノメチル）−１，２，３−トリアゾル−４−イル）メチル）−３−（ｓ）−（４−フルオロフェニル）モルホリン化合物の製造方法
AU1230000A (en) 1998-10-30 2000-05-22 Merck & Co., Inc. Linear process for the preparation of a morpholine compound
ES2214060T3 (es) * 1998-12-29 2004-09-01 PHARMACIA & UPJOHN COMPANY Procedimiento para la preparacion de arileteres.

Also Published As

Publication number Publication date
PL359137A1 (en) 2004-08-23
AU2001268170A1 (en) 2001-12-17
SK17082002A3 (sk) 2003-04-01
CN1436178A (zh) 2003-08-13
EA200300002A1 (ru) 2003-04-24
AR030284A1 (es) 2003-08-20
CN1182125C (zh) 2004-12-29
CZ20024013A3 (cs) 2003-03-12
CA2410404A1 (en) 2001-12-13
US6600040B2 (en) 2003-07-29
JP2003535852A (ja) 2003-12-02
HRP20020973A2 (en) 2005-02-28
BR0111472A (pt) 2004-01-06
US20020052494A1 (en) 2002-05-02
WO2001094324A1 (en) 2001-12-13
EA004743B1 (ru) 2004-08-26
KR20030007887A (ko) 2003-01-23
NZ523389A (en) 2004-08-27
MXPA02012101A (es) 2003-04-25
EP1292584A1 (en) 2003-03-19
HUP0400491A2 (hu) 2004-06-28

Similar Documents

Publication Publication Date Title
IL152793A0 (en) PROCESS FOR THE SYNTHESIS OF (2R, 2-ALPHA-R, 3a)-2-[1-(3,5-BIS(TRIFLUOROMETHYL)PHENYL]-3-(4-FLUOROPHENYL)-1,4-OXAZINE
MXPA03005284A (es) Nuevo procedimiento para la sintesis de fenilamida del acido 5-(4-flourofenil) -1-[2-((2r, 4r)-4-hidroxi -6-oxotetrahidro -piran-2-il) -etil]-2-isopropil -4-fenil-1h -pirrol-3-carboxilico.
IL157478A0 (en) Method for the synthesis of 2', 3'-didehydronucleosides
PL343726A1 (en) 1-[(1-substituted-4-piperidinyl)methyl]-4-piperidine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds
DE60111734D1 (de) [1,4']-bipiperidin verbindungen
GB0031103D0 (en) Chemical compounds
DE60218434D1 (en) 4-(2-BUTYLAMINO)-2,7-DIMETHYL-8-(2-METHYL-6-METHOXYPYRID-3-YL) PYRAZOLO- 1,5-Aö-1,3,5-TRIAZIN, SEINE ENANTIOMEREN UND PHARMAZEUTISCH ANNEHMBARE SALZE ALS CORTICOTROPIN-RELEASING-FACTOR-REZEPTOR-LIGANDEN
TWI341313B (en) Process for the synthesis of 5-[[2(r)-[1(r)-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3(s)-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3h-1,2,4-triazol-3-one
AU2001269749A1 (en) Trans-glycosidation process for the synthesis of (2r, 2-alpha-r, 3a)-2-(1-(3,5-bis(trifluoromethyl)phenyl) ethoxy)-3-(4-fluorophenyl)-1,4-oxazine
AU2001266690A1 (en) Process for the synthesis of (2r, 2-alpha-r)-4-benzyl-2-(1-(3,5-bis(trifluoromethyl)phenyl) ethoxy)-1,4-oxazin-3-one
IL153836A0 (en) Novel form of (r)-n-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide
NO20024352D0 (no) Trinnvis alkylering av 5-substituerte 1-(4-fluorfenyl)-1,3- dihydroisobenzofuraner
ID21499A (id) Proses untuk memproduksi n-(4-fluorofenil)-n-(1-metiletil)-2-[(5-(trifluorometil)-1,3,4-tiadiazol-2-il)-oksi]-asetamida
AU2001268290A1 (en) Intramolecular glycosidation process for the synthesis of (2r, 2-alpha-r, 3a)-2-(1-(3,5-bis(trifluoromethyl)phenyl) ethoxy)-3-(4-fluorophenyl)-1,4-oxazine
MXPA03002926A (es) Proceso para la sintesis de 2,2,6,6,-tetrametil-4--oxipiperidina.
IL155706A0 (en) Process for the preparation of (r)-5-(2-benzenesulfonylethyl)-3-(n-methylpyrrolidin-2-ylmethyl)-1h-indole
IL129647A0 (en) Substituted 4-(6-fluoro-(1H)-indol-3-YL)-1,2,3,6-tetrahydropyridine for the treatment of CNS-disorders
AU2003222435A8 (en) Process for the preparation of 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)- 1,3-dihydro-5-isobenzofuran carbonitrile
SE0102809D0 (sv) Novel compounds
MXPA03006970A (es) Nuevo uso de iloperidona.
HK1051190A1 (en) Process for the preparation of 2-(4-alkyl-1-piperazinyl-benzaldehyde and -benzylidenyl compounds.
IL164377A (en) Methods of preparation of 2-(7-chloro-1,8-naphthyridine-2yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone
AU2002230961A1 (en) Process for the synthesis of 1-(3,5-bis(trifluoromethyl)-phenyl)ethan-1-one
ZA200404652B (en) Preventives or remedies for alzheimer's disease or amyloid protein fibrosis inhibitors containing nitrogen-containing heteroaryl compounds.
HUP0203476A3 (en) Sodium 2-(4,6-dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionate, use thereof and pharmaceutical composition containing the same